Description
Key facts
Cell type:Hep G2,
Species or organism:Human,
Tissue:Liver,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon4.,
Disease:Hepatocellular Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ARRB2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Beta-arrestin 2 also known as arrb2 or b-arrestin mechanically functions to regulate G protein-coupled receptor (GPCR) signaling. This protein has a molecular mass of approximately 47 kDa and is ubiquitously expressed across various tissues including the brain lungs and heart. Beta-arrestin 2 works by binding to phosphorylated GPCRs facilitating receptor desensitization and endocytosis which stops the receptor's signaling activity and mediates receptor internalization.
Biological function summary
Beta-arrestin 2 plays an important role in mediating signal transduction pathways beyond GPCR desensitization including those involved in cell communication and cellular response regulation. Beta-arrestin 2 interacts with multiple signaling proteins to form complexes that facilitate signaling pathways notably influencing MAPK (Mitogen-Activated Protein Kinase) pathways. It provides a scaffold for downstream signaling molecules affecting cell signaling outcomes.
Pathways
Beta-arrestin 2 significantly participates in two important biological pathways: the MAPK pathway and the Wnt signaling pathway. Through these pathways beta-arrestin 2 interacts with signaling proteins such as ERK1/2 (Extracellular signal-Regulated Kinases) and dishevelled proteins. These interactions highlight beta-arrestin 2's ability to modulate signal strength and duration contributing to diverse cellular responses.
Beta-arrestin 2 is implicated in conditions like heart failure and certain cancers. The aberrant regulation of beta-arrestin 2-related pathways can lead to uncontrolled cell proliferation or inadequate heart responses. Additionally beta-arrestin 2 is connected to proteins like GPCR kinases in the context of heart failure and MAPK proteins within oncogenic processes underlining its potential as a therapeutic target.
